Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  649 results for ""GLUCAGON-like peptide-1 receptor""

Your Filters

Subject : hypoglycemia
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience.

  • Authors : Marshall S; Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States. .; Alabama Poison Information Center, Children's of Alabama, Birmingham, Alabama, United States. .

Subjects: Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists ; Poison Control Centers* ; Hypoglycemic Agents*/Hypoglycemic Agents*/Hypoglycemic Agents*/adverse effects

  • Source: Journal of medical toxicology : official journal of the American College of Medical Toxicology [J Med Toxicol] 2024 Jul 11; Vol. 20 (3), pp. 278-285. Date of Electronic Publication: Publisher: Springer Country of Publication: United States NLM ID: 101284598 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review.

  • Authors : Llewellyn DC; Department of Endocrinology, King's College Hospital NHS Foundation Trust, London, UK.; Logan Ellis H

Subjects: Bariatric Surgery*/Bariatric Surgery*/Bariatric Surgery*/adverse effects ; Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists ; Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/therapeutic use

  • Source: Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2023 Jan; Vol. 31 (1), pp. 20-30. Date of Electronic Publication: 2022 Dec 10.Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101264860 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Evaluation of GLP-1 Receptor Agonists in Combination With Multiple Daily Insulin Injections for Type 2 Diabetes.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists ; Hypoglycemia*/Hypoglycemia*/Hypoglycemia*/epidemiology

  • Source: Journal of pharmacy practice [J Pharm Pract] 2022 Dec; Vol. 35 (6), pp. 979-990. Date of Electronic Publication: 2021 Apr 29.Publisher: Sage Publications Country of Publication: United States NLM ID: 8900945 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

GLP-1 receptor agonist use during hospitalisation: Better glycaemic control compared to premixed insulin.

  • Authors : Jervis M; Faculty of Life Sciences & Medicine, King's College London, London, UK.; Mitchell AP

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists ; Glycemic Control*

  • Source: Diabetes/metabolism research and reviews [Diabetes Metab Res Rev] 2022 Nov; Vol. 38 (8), pp. e3574. Date of Electronic Publication: 2022 Sep 06.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883450 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials.

  • Authors : Maiorino MI; Unit of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples 80138, Italy. Electronic address: .; Chiodini P

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists ; Hypoglycemia/Hypoglycemia/Hypoglycemia/*prevention & control

  • Source: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2019 Aug; Vol. 154, pp. 101-115. Date of Electronic Publication: 2019 Jun 22.Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Jan; Vol. 20 (1), pp. 165-172. Date of Electronic Publication: 2017 Aug 22.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.

  • Authors : Shaw JE; Baker Heart and Diabetes Institute, Melbourne, Australia.; Gallwitz B

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2017 Dec; Vol. 19 (12), pp. 1793-1797. Date of Electronic Publication: 2017 Jul 25.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.

  • Authors : Mathieu C; Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium.; Del Prato S

Subjects: Insulin Resistance*; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Aug; Vol. 20 (8), pp. 2023-2028. Date of Electronic Publication: 2018 May 02.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.

  • Authors : Barnett AH; Heart of England NHS Foundation Trust and University of Birmingham, Birmingham, UK.; Arnoldini S

Subjects: Models, Economic*; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Aug; Vol. 20 (8), pp. 1921-1927. Date of Electronic Publication: 2018 May 03.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.

  • Authors : Kaku K; Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.; Yamada Y

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists ; Glucagon-Like Peptides/Glucagon-Like Peptides/Glucagon-Like Peptides/*administration & dosage

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 May; Vol. 20 (5), pp. 1202-1212. Date of Electronic Publication: 2018 Feb 21.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  649 results for ""GLUCAGON-like peptide-1 receptor""